A Phase 2 interventional study of TDF - 245mg or TAF -25mg associated to 3TC - 300mg or FTC - 200mg and a NNRTI or PI/r or INSTI and Dual therapy with 3TC in combination with DTG or ritonavir-boosted Darunavir (rDVR) in HIV Infections and HBV Coinfection, sponsored by ANRS, Emerging Infectious Diseases. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-02-05.
Sponsored by ANRS, Emerging Infectious Diseases · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 98 studies testing tenofovir in HIV Infections — 1 open to participants now, 3 under way, 1 of them phase 3. Tenofovir · HIV Infections.
Among the 98 studies testing tenofovir in HIV Infections, this one is the 38th largest by planned enrollment of the 94 interventional ones that give a count, is the only one that started in 2025, is one of 22 in phase 2, and was the 97th registered.
4,737 studies on the registry are indexed under HIV Infections; 247 are open to participants now.
Browse HIV Infections studies →1 of the 98 studies testing tenofovir in HIV Infections is open now.
Tenofovir: first FDA approval 2001 (VIREAD), first EMA approval 2002. What it is approved for, and how studies give it, is on its page →
Of the 159 HIV Infections studies recruiting now, 104 (65%) set no upper age limit and 42 (26%) stop at 75 or younger; 31 take children under 18; 60 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
98 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 14 · Phase 2 26 · Phase 3 20 · Phase 4 27
First in 1999; this study’s year is marked. 1 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 140 is above the median of 80 across 3,492 interventional studies indexed under HIV Infections.
Median enrollment 99 across the 94 interventional studies. Of the 82 that completed or were terminated, 25 (30%) have results posted.
This tab as a report to print or save as PDF → With an account.
23 of 98 have an industry lead sponsor. The 10 most frequent:
ANRS, Emerging Infectious Diseases is the lead sponsor of 215 studies on the registry; 38 are open to participants now.
73 studies in HIV Infections by ANRS, Emerging Infectious Diseases: 12 open now, 13 under way, none of them phase 3. Of 47 finished, 2 (4%) have results posted.
Among the 73 studies in HIV Infections by ANRS, Emerging Infectious Diseases, this one is the 32nd largest by planned enrollment of the 50 interventional ones that give a count, is one of 3 that started in 2025, is one of 11 in phase 2, reaches primary completion later than 9 of the 12 other live ones, and was the 67th registered.
ANRS, Emerging Infectious Diseases’s HIV Infections studies by the year they started, since 1997.
1 of the studies testing tenofovir in HIV Infections that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06338826ANRS, Emerging Infectious DiseasesStudy Evaluating the Safety, in Terms of HBV Virological Control At 96 Weeks, of 2 Antiviral Treatment Relief Strategies, in Patients Co-infected with the HIV-1 and HBV Viruses | 2027-09-30 |
Add it to your calendar (.ics) → With an account.
Among the 98 studies testing tenofovir in HIV Infections, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among ANRS, Emerging Infectious Diseases’s 73 in HIV Infections:
This tab as a report to print or save as PDF → With an account.
The main objective of this study is to evaluate at 96 weeks the safety with respect to hepatitis B control of 2 treatment reduction strategies for patients with previously controlled HIV-HBV co-infection on continuous triple therapy
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Current daily antiretroviral tritherapy not modified for ≥ 12 months must including tenofovir disoproxil fumarate (TDF) 245mg or tenofovir alafenamide fumarate (TAF -25mg) associated to lamivudine (3TC - 300mg) or emtricitabine (FTC - 200mg) and a NNRTI or PI/r or INSTI to choose from
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
- Arm 1 (reference arm): Continuation of continuous (7 days/week) triple antiviral therapy including TDF or TAF
- Arm 2 (T4): Relief from previous triple antiviral therapy (containing TDF or TAF) on 4 out of 7 consecutive days
Drug: TDF - 245mg or TAF -25mg associated to 3TC - 300mg or FTC - 200mg and a NNRTI or PI/r or INSTI
Switch from prior triple antiviral therapy (containing TDF or TAF) to continuous dual therapy without TDF or TAF but including 3TC in combination with Dolutegravir (DTG) or ritonavir-boosted Darunavir (rDVR
Drug: Dual therapy with 3TC in combination with DTG or ritonavir-boosted Darunavir (rDVR)
Drug page: TenofovirStudies of TenofovirTenofovir pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.
The study will include patients under current daily antiretroviral tritherapy not modified for ≥ 12 months must including tenofovir disoproxil fumarate (TDF) 245mg or tenofovir alafenamide fumarate (TAF -25mg) associated to lamivudine (3TC - 300mg) or emtricitabine (FTC - 200mg) and a NNRTI or PI/r or INSTI to choose from * NNRTI = efavirenz, rilpivirine, etravirine, doravirine * PI/r = atazanavir/r ou darunavir/r * INSTI = bictegravir, dolutegravir, elvitegravir/cobicistat, raltegravir
dual therapy without TDF or TAF but including 3TC in combination with Dolutegravir (DTG) or ritonavir-boosted Darunavir (rDVR
The proportion of participants with HBV virological failure at 96 weeks.
HBV virologoical failure is defined by 2 successive varial load ≥ 10UI/ml
Time frame: 96 weeks
• HBV virological success rate at 48 weeks
HBV virological success is defined by a viral load ≤10 UI/ml
Time frame: at Week 48
• HIV virological success rate at 48 and 96 weeks
HIV virological success is defined by a viral load ≤ 50 cp/ml
Time frame: At week 48 and week 96
• Time to virological failure (rebound HBV and/or HIV viral load)
Time frame: between Week 0 and Week96
• The rate of participants with at least one HBV viral load blip until W48 and until W96
a blip is defined by a HBV viral load \>10UI/mL followed by a control value ≤ 10UIml
Time frame: At week 48 and week 96
• Selection of HBV resistance mutations at the time of virological failure
Time frame: between Week 0 and Week 96
• Incidence of grade 3 or higher adverse events of grade 3 or higher, incidence of adverse events and incidence of strategy discontinuation of the strategy at W48 and W96
Time frame: At week 48 and week 96
• Evolution of CD4 from W0 to W48 and W96
Time frame: Week 0 to Week 48 and week 96
• Evolution of total cholesterol from W0 to W48 and W96
Time frame: from Week 0 to Week 48 and Week 96
• Evaluation of the adherence by self-reported questionnaire
without analysis scale
Time frame: at Week 0, Week 12, Week 24, Week 48, Week 72 and Week 96
• Evaluation of quality of life using the Pro-Qol self-questionnaire
without analysis scale
Time frame: at Week 0, Week 12, Week 24, Week 48, Week 72 and Week 96
Evolution of CD8 T lymphocytes from W0 to W48 and W96
Time frame: Week 0 to Week 48 and week 96
Evolution of the CD4/CD8 ratio from W0 to W48 and W96
Time frame: Week 0 to Week 48 and week 96
Evolution of LDL-c from W0 to W48 and W96
Time frame: from Week 0 to Week 48 and Week 96
Evolution of HDL-c from W0 to W48 and W96
Time frame: from Week 0 to Week 48 and Week 96
Evolution of triglycerides from W0 to W48 and W96
Time frame: from Week 0 to Week 48 and Week 96
Evolution of fasting blood sugar from W0 to W48 and W96
Time frame: from Week 0 to Week 48 and Week 96
HBV virological success rate at 96 weeks between arms
HBV virological success is defined by a viral load ≤10 UI/ml
Time frame: at Week 96
No study locations are listed for this record.
Plan to share: Undecided
No publications or documents are linked to this record.
Start is estimated for Feb 2025; primary completion for Sep 2027, 31 months later.
Of 64 non-industry phase 2 interventional studies under HIV Infections, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 74. This study's planned 31 months is below that.
Counting every sponsor, half of 98 studies reached it within 31 months; a quarter within 17 and three quarters within 58.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Jan 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Tenofovir
ANRS, Emerging Infectious Diseases →